Intro

This chapter discusses the comparison between tenecteplase and alteplase in bridging therapy for patients with large ischemic cores, drawing insights from two major French registries. The conversation underscores the necessity for additional data and the impact of treatment options on patient outcomes in severe ischemic stroke cases.